Because of missing samples, cytokines were obtained only in a subgroup of 108 participants.
We excluded 25 patients because of missing samples, and 2 patients were excluded because of unknown outcomes and/or missing patient data.
Because of missing samples for subjects 5, 11, and 12, it was not possible to define the elimination-phase parameters for these subjects, and the area under the dexmedetomidine concentration-time curve extrapolated to infinity (AUC0-∞) was estimated by using the mean elimination half-life of the other patients.
Participants excluded from analysis because of missing urine sample (n = 1,064) had similar sociodemographic characteristics as the analyzed cohort (data not shown).
Additional subjects were excluded because of missing plasma sample (n = 28) or inability to determine the Hp genotype (n = 13), leaving 436 subjects with diabetes and 526 controls in the analyses.
Other limitations included the study size because of numbers of patients recruited, missing samples when patients could not be located, the lack of pyrazinamide susceptibility testing, and some uninterpretable contaminated cultures.
Because of the missed samples and the small number of subjects completing the blood sampling procedures, it was not possible to analyze the parameters of pulsatile LH secretion.
We enrolled 485 patients; of these, we excluded 116 cases because of known immune deficiency and 19 cases because of missing plasma samples, leaving 350 subjects for analysis.
